版本:
中国

BRIEF-Galectin Therapeutics updates on completion of Nash Cx trial

June 13 Galectin Therapeutics Inc:

* Galectin therapeutics announces important milestones towards completion of Nash Cx trial

* As of time of their evaluation, therapy had been completed in 68% of subjects in Nash-Cx trial​

* ‍Independent data safety monitoring board recently concluded from safety perspective, company's Nash-Cx trial should continue​

* ‍Panel recently met to review safety data of all enrolled subjects who had completed trial​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐